Arsenic trioxide
(ATO) is effective in the treatment of hematological
malignancies and solid tumors. However, its toxicity and side effects
are severe, posing an obstacle in its clinical application. A controlled-release
ATO carrier with mitochondrial targeting was constructed in this study.
The safety and efficacy in vitro were investigated using a hemolysis
test, cytotoxicity, proliferation, migration, apoptosis, and other
changes in cell behavior. The safety and efficacy were further evaluated
in vivo by hematoxylin–eosin staining, terminal deoxyribonucleotide
transferase-mediated dUTP nick end labeling staining, and blood testing
in tumor-bearing mice. Immunohistochemically and western blotting
experiments were conducted to explore the mechanism of combination
therapy of material-based chemotherapy and microwave hyperthermia
in vitro. We demonstrated that the nano-zirconia (ZrO2)
loading platform may be used to administer the ATO, with local precision-controlled
release and mitochondrial targeting. Furthermore, we showed the safety
of this approach for delivering high doses of ATO. In addition, we
explored this new method in combination with in vitro microwave heat
therapy, providing a potentially novel intravenous approach to chemotherapy.
We described a new non-invasive treatment that improved the efficacy
of ATO chemotherapy against hepatocellular carcinoma through nano-ZrO2 carriers.